

### EU actions against cancer

Jan-Willem van de Loo, Phd
Policy Officer
Team Lead Cancer
Directorate E - PEOPLE
DG Research & Innovation
European Commission

**2<sup>nd</sup> iPAAC Stakeholder Forum Brussels, 10 December 2019** 

#### Addressing the growing burden of cancer





#### **Challenges ('barriers')**

- Prevent the preventable
- Combine interventions
- Proven 'personalised medicine' benefits?
- Implementation Changing healthcare landscape
- Health inequity and inequality health literacy, access, pricing


#### **EU** approach ('solutions')

- Comprehensive: prevention, cure, care, quality of life
- Improve uptake in health systems impact for citizens
- Focus on EU-added value
- Use partnerships
- Foster innovation





### **Cancer research What EU has supported**



- collaborative research
- training
- frontier
- innovation

#### **Translational research**

- tumour-host environment
- risk factors, biomarkers,
- prevention, early detection
- imaging
- models, technologies
- large data, cloud computing
- all possible treatment options, immunobiology and therapy

**Investigator-driven trials** 

Palliative & end-of-life care

**Cost-effectiveness** 





Emphasising the European Union's Commitment to Cancer Research:
A Helicopter View of the Seventh Framework Programme for
Research and Technological Development


JAN-WILLEM VAN DE LOO, DOMINIKA TRZASKA, KARIM BERKOUK, MARIA VIDAL, RUXANDRA DRAGIIA-AKLI

European Commission, Health Directorate, Directorate General for Research and Innovation,
Brussels, Belgium


€3.1 billion (2007-2019)

> focus on solutions for patients, innovation, close-to-market

#### **EU funded cancer research - H2020**



#### **EU Cancer connections**



### **Towards person-centred care Personalised medicine**

**Prevention** 

**Aetiology** 

Diagnosis / Prognosis

Model Systems

**Therapy** 

Survivorship / QoL

Stratification and high-risk groups

**Screening** 

**Vaccines** 

Molecular understanding of disease

Resistance

Metastasis

Molecular classification of cancer subtypes

Biomarker identification for:

- Diagnosis
- Prognosis
- Prediction
- Monitoring

**Medical Imaging** 

**Companion** diagnostics

**Devices** 

**Animal models** 

In silico models

In vitro, in vivo & ex-vivo models (xeno patients, avatars)

**Modelling** 

Surgery, chemo, radiotherapy, targeted drugs, devices

**ATMPs** 

Big data, cloud, Artificial intelligence

CTs, novel CT design

Identification of sub-groups

PROMs: depression, pain, fatigue, cachexia, infertility

Palliative and end-of-life care













#### Personalised breast cancer prevention




Towards improved screening for breast, cervical and colorectal cancer in all of Europe



**Adapting Breast Cancer Screening Strategy Using Personalised Risk Estimation** 



Randomized, Comparison Of Risk-Stratified versus Standard Breast Cancer Screening In European Women Aged 40-74



#### Patient-centred quality-of-life portfolio



Validated **predictive models of radiotherapy toxicity** to improve quality-of-life and reduce side-effects in 5300 breast, lung, prostate cancer survivors



Advance Care Planning; an **Innovative Palliative Care Intervention** to Improve Quality of Life in Cancer
Patients - a Multi-Centre Cluster Randomized Clinical Trial



Randomised controlled trial to evaluate electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology for home-based care of patients with advanced cancer















# Working in partnerships

# Public - Public partnerships: Coordination of national research actions (1)





- Linking national/regional cancer registries and bio-banks to improve quality of data collection, optimise cancer control in Europe and evaluate therapy effectiveness
- Basis for creation of European Cancer Information System (ECIS)
- Linking national/regional and charity funding organisations in MS on translational cancer research.
- > 1st joint call on 'Tumour heterogeneity'
- 2<sup>nd</sup> joint call on 'Immunotherapy'
- 3rd joint call on 'Early detection and/or progression'
- > 4th joint call on 'Translational Research on Rare Cancers'

RESEARCH FUNDING

Toward Variable Funding for International Science

European ERA-NETs offer lessons for flexible international funding to better meet the needs of science and society.

# Public – Public partnerships: Coordination of national research actions (2)

#### The International Consortium for Personalised Medicine – IC PerMed – 30 Funders

Establish Europe as a global leader in PM research

Support PM science-base via a **coordinated research approach**Support research to **demonstrate benefits** of PM to citizens and healthcare systems
Prepare for PM approaches for citizens


MOH

#### Implementation based on PerMed Strategic Research Agenda

ICPerMed Action Plan: 22 research, 8 support actions.

EUScienceAlmovation 0 distributoriones - 20s
Onco out the recoming published an Online has action Plan to boost sinessanch &
representation of first monotone-blockore is counted authorisect/hosts.

Action Plan
Assemble the residual adaptions Assemble has action and the second authorisect/hosts.



Policy, Funders, Researchers,

#### **Public - Private partnership** The Innovative Medicines Initiative



#### **CancerID**

Circulating tumour cell based biomarkers

#### **MARCAR**

Cancer risk biomarkers







#### **Quic-Concept** Clinical Imaging biomarkers

**ONCOTRACK** Omics,

xenopatients

#### From biomarkers to models to big data



**PREDECT** In vitro models

#### HARMONY, **PIONEER**

outcome data haematological and prostate cancers





ITCC-P4 Paediatric cancers PoC platform

#### Latest and future calls:

- Patient-reported outcomes and quality of life endpoints
- > CAR-T
- **Proton versus photon therapy oesophageal cancer**
- **Real-world implementation liquid biopsies**



# International Partnerships The Global Alliance for Chronic diseases

- Address non-communicable diseases in LMICs and vulnerable populations in HICs
- Focus on **implementation research** and scaling up interventions in non-communicable diseases

#### Coordinated call on cancer in 2020

"Further research is needed to adapt existing approaches to produce meaningful advice that accounts for the complexity of health

systems, political systems, and contexts."

(Lewin, Bosch-Capblanch, Oliver et al., PLoS Medicine, 2012)



#### **Next steps**



**Horizon Europe Strategic Planning** 



**Horizon Europe Mission for Cancer** 




**EU Action Plan against Cancer** 

"Survival rates are on the up, especially thanks to early detection and screening programmes. But there is a lot more we can do. I will put forward a **European plan to fight cancer**, to support Member States in improving cancer control and care."

<u>Ursula von der Leyen, European Commission President</u>

#### Horizon Europe - evolution not revolution

Specific objectives of the Programme





#### **Horizon Europe - Missions**

- Strong visibility and impact
- Achieve a bold, inspirational and measurable goal within a set timeframe
- Find solutions to some of the major challenges faced by European citizens




#### **Horizon Europe – what Missions are NOT**

Missions are an entirely new approach based on portfolios of actions working towards broadly defined goals, and should not be confused with existing methods and instruments i.e. missions are not the same as

- R&I Programmes
- R&I Partnerships
- Focus Areas from Horizon 2020
- Single projects or topics
- Horizon Europe Clusters



#### **Actors in Mission Co-Design**





#### Mission Sub-groups of the Shadow Programme Committee

- Regular meetings with the Commission and members of Mission Boards for open exchange on identification of specific missions in the Horizon Europe Strategic Plan (early 2020)
- Feedback to the Horizon Europe Shadow Programme Committee
- Identify key national events for co-design of missions with citizens
- Identify relevant national programmes to join forces for accomplishing the missions



#### **Cancer Mission Board - members**

#### Chair



Walter RICCIARDI (IT)



**Christine CHOMIENNE (FR)** 



Regina **BEETS-TAN (NL)** 



Serban **GHIORGHIU (RO)** 



**Fiona GODFREY (BE)** 



**Ruth** LADENSTEIN (AT)



Marcis LEJA (LV)



Tomi MÄKELÄ (FI)



**Andres METSPALU (EE)** 



Martin PICCART (BE)



**Pedro** PITA BARROS (PT)



**Kondrad** RYDZYNSKI (PL)



**Anne Lise** RYEL (NO)



**Bettina** RYLL (DE)



**Elisabete WEIDERPASS (SE)** 

#### **Cancer Mission Board - role**

#### Mission Boards will advise the European Commission on:

- Identification of one or more missions in the respective mission area, with input from stakeholders and citizens
- Content of work programmes, with input from stakeholders and citizens
- Characteristics of project portfolios for missions
- Adjustment actions, or termination if appropriate
- Selection and briefing of independent expert evaluators, specific evaluation criteria and their weighting;
- Framework conditions which help achieve the objectives of the mission
- Communication
- Policy coordination/synergies
- Key performance indicators





### Thank you!

#### #HorizonEU

**Horizon Europe dedicated website** 

http://ec.europa.eu/horizon-europe

**European Innovation Council** 

http://ec.europa.eu/research/eic

**EU** budget for the future

http://ec.europa.eu/budget/mff/index\_en.cfm